Sustained release formulation using non-aqueous membrane emulsification

JP2023551446A5Pending Publication Date: 2024-11-28REGENERON PHARMACEUTICALS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023530680
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-11-25
Filing Date
2021-11-24
Publication Date
2024-11-28

AI Technical Summary

Technical Problem

Existing aqueous emulsion systems for drug delivery face challenges such as protein degradation, precipitation, and poor size control of microspheres, leading to instability and inefficiencies in sustained release formulations.

Method used

A non-aqueous film emulsion method using hydrocarbon-in-fluorocarbon emulsions is employed, where micronized protein powder and polymer are combined in a hydrocarbon solvent, forming a suspension that is emulsified with a fluorocarbon liquid and fluorosurfactant, followed by solvent removal to create stable, controlled-size microspheres.

Benefits of technology

This method achieves improved protein stability and controlled size distribution, resulting in sustained release formulations with high encapsulation efficiency and minimal burst release, suitable for therapeutic proteins like VEGF traps.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

A non-aqueous membrane emulsion method for producing polymer and polymer-coated microparticles is provided. Some embodiments provide a method for producing sustained- or controlled-release microparticles by combining a micronized protein powder and a polymer in a hydrocarbon solvent to form a first non-aqueous solution, agitating the first non-aqueous solution to form a suspension, and feeding the suspension into a dispersion pump. The suspension is then injected through a porous membrane into a continuous phase comprising a fluorocarbon liquid and a fluorosurfactant to form a hydrocarbon-in-fluorocarbon emulsion. The hydrocarbon solvent, fluorocarbon liquid, and fluorosurfactant are removed, and the microparticles are collected.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This application claims the priority of U.S. Application No. 63 / 118,264, filed on November 25, 2020, which is incorporated herein by reference.

[0002] Aspects of the present invention generally relate to methods of making drug microsphere formulations and non-aqueous emulsion systems produced by membrane emulsification methods for use in making them.

Background Art

[0003] The sustained delivery of therapeutic proteins to biologically relevant targets is desirable for the treatment of medical conditions such as cancer, cardiovascular disease, vascular pathologies, orthopedic disorders, dental disorders, wounds, autoimmune diseases, gastrointestinal disorders, and eye diseases. Biocompatible and biodegradable polymers and other implantable delivery devices for the controlled and extended delivery of drugs have been used for decades. For example, in some polymer-based delivery devices, the therapeutic agent is slowly released as the polymer degrades over time.

[0004] Sustained release may be desirable for patient compliance. In particular, reducing the number of injections can be beneficial, especially in cases where a physician needs to perform the injection, such as in the case of intravitreal therapeutic agents. The medical need for sustained release formulations to effectively deliver drugs over time with as few injections as possible is not met. In other diseases, such as cancer and inflammatory diseases, there is a need for improvement in implantable sustained release formulations containing stable and effective protein therapeutics.

[0005] Therapeutic macromolecules such as antibodies, receptor Fc fusion proteins, trap proteins, and mini-trap proteins must be formulated not only to make the molecules suitable for administration to patients, but also to maintain their stability during storage and at the administration site. For example, therapeutic proteins (e.g., antibodies and fusion proteins) in aqueous solutions are susceptible to degradation, aggregation, and / or undesirable chemical modifications unless the solution is properly formulated. The stability of protein therapeutics in liquid formulations depends not only on the type of excipients used in the formulation, as well as the amount of those excipients and their proportions to each other, but also on the concentration of the soluble protein. When preparing therapeutic protein formulations, considerations other than stability must also be taken into account. Examples of such additional considerations include the viscosity of the solution and the concentration of the therapeutic protein, which can be adjusted by a given formulation. When formulating therapeutic proteins for sustained release, great care must be taken to arrive at a formulation that maintains stability over time at storage and physiological temperatures, contains an appropriate concentration of antibody, and has other properties that allow the formulation to be conveniently administered to patients.

[0006] Several sustained-release formulations are manufactured using a variety of encapsulation methods, including internal phase separation, interfacial polymerization, multi-emulsion formation, layer-by-layer adsorption of polyelectrolytes, and flexible template techniques. Water in oil in water (W / O / W) multi-emulsions are the most common type of multi-emulsion, allowing for the direct encapsulation of an aqueous / hydrophilic core in an aqueous suspension. Unfortunately, aqueous emulsion systems have certain problems when used to encapsulate biological activators in sustained-release formulations. For example, protein precipitation occurs at the aqueous-organic interface, simultaneously reducing their immunoreactivity (Raghuvanshi, R., et al., Pharm Dev Technol, 3(2):269-76 (1998)). In some aqueous emulsion systems, water can diffuse into the organic phase and hydrolyze proteins. After hydrolysis, protein droplets begin to fuse, escape into the aqueous environment, and aggregate or precipitate. After curing, voids and water channels appear in the microparticles as the proteins escape into the aqueous environment.

[0007] When the presence of water is undesirable, non-aqueous emulsions can be used instead of conventional aqueous emulsions. However, there are few reports on non-aqueous emulsions in the literature or prior art. Two types of hydrocarbon-based non-aqueous emulsion systems are known: (1) two immiscible organic solvents stabilized by blocking copolymers (e.g., hexane / dimethylformamide), and (2) oil-immiscible polar solvents (e.g., formamide, acetonitrile) used in place of water with existing surfactants. Perfluorinated water-in-oil (W / F) emulsions have been widely studied and applied to droplet-based microfluidics for single-cell or single-molecule bioassays. In these studies, PFPE-PEG-PFPE has been used as a fluorinated surfactant (FS) to stabilize water droplets in fluorocarbon solvents.

[0008] While many miscible solvent pairs (usually a pair of one polar solvent and one nonpolar solvent) are available, the challenge lies in finding a suitable pair for the synthesis of polymer microspheres. Typical biodegradable polymers, such as poly(lactide-co-glycolide) (PLGA), polylactic acid (PLA), and poly(orthoester) (POE), are mostly soluble in moderately polar solvents such as chloroform, dichloromethane, and ethyl acetate. This limits the selection of continuous phases. In addition, process compatibility, toxicity, safety, and residual solvents are concerns about using these organic solvents and must be considered for use as pharmaceuticals.

[0009] Fluorocarbons can be used as a continuous phase in non-aqueous emulsion systems due to the following general properties: 1. Fluorocarbons are neither hydrophobic nor hydrophilic, are miscible with most organic (hydrocarbon) solvents, and are ideal as a continuous phase for hydrocarbon droplet emulsions. 2. Fluorocarbons are nonsolvents of proteins and other hydrophilic molecules, hydrocarbon polymers, and organic excipients; that is, these types of molecules are not soluble in fluorocarbons. 3. Fluorocarbons have low viscosity. 4. Fluorocarbons are chemically inert and may be relatively less toxic or corrosive compared to commonly used hydrocarbon solvents. 5. Fluorocarbons are volatile and recyclable.

[0010] Previous literature has reported that various types of emulsion systems containing fluorocarbons have been prepared by microfluidic methods, such as water in fluorocarbon (W / F), water in fluorocarbon (W / F / W) biemulsions, water / fluorocarbon / oil / water (W / F / O / W) tripleemulsions, fluorocarbon / hydrocarbon / water (F / H / W) biemulsions, and hydrocarbon / fluorocarbon / water (H / F / W) biemulsions. Some of these emulsions have been used in the synthesis of polymer microspheres. However, all of them are aqueous-based emulsion systems that use water as either a dispersed or continuous phase.

[0011] Regardless of the type of emulsion used, the size distribution of microspheres or particles is typically broad, and it is not possible to easily control the size and fill the target without extensive process optimization and control strategies. Therefore, there remains a need to develop new methods for controlling microsphere or particle size to fill the target without extensive process optimization and control strategies.

[0012] Therefore, the object of the present invention is to provide a non-aqueous membrane emulsion system and method for producing drug formulations, as well as methods for using them.

[0013] Another object of the present invention is to provide a sustained-release formulation having improved protein stability, stable sustained release, and a controlled size distribution. [Overview of the Initiative]

[0014] A non-aqueous membrane emulsion method for producing polymers and polymer-coated microparticles is provided. Several embodiments provide a method for producing sustained-release or controlled-release microparticles by combining a micronized protein powder and a polymer in a hydrocarbon solvent to form a first non-aqueous solution, stirring the first non-aqueous solution to form a suspension, and supplying the suspension into a dispersion cell, wherein the suspension is injected into a continuous phase containing a fluorocarbon liquid and a fluorinated surfactant via a porous membrane under contiguous flow of the continuous phase to form a hydrocarbon emulsion in a fluorocarbon (membrane emulsification). The method further comprises the steps of adding a hydrofluoroester to the hydrocarbon emulsion in a fluorocarbon and removing the hydrocarbon solvent from the hydrocarbon phase to provide cured microparticles. In some embodiments, a mixture of the hydrofluoroester and the fluorocarbon is added to the emulsion to assist in the removal of hydrocarbons. In some embodiments, the method subsequently includes adding an additional pure hydrofluoroester to the emulsion. The method further comprises removing the fluorocarbon liquid to isolate the microparticles, which contain proteins encapsulated within a polymer matrix. This method optionally includes washing the fine particles in the fluorocarbon liquid to remove residual fluorinated surfactants, removing the fluorocarbon liquid, and collecting the fine particles by, for example, vacuum filtration. In some embodiments, a polyethersulfone membrane filter is used for vacuum filtration. In some embodiments, the protein powder is prepared from an antibody or its antigen-binding fragment, fusion protein, or recombinant protein. In some embodiments, the protein is a VEGF trap protein, such as aflibercept. In some embodiments, the emulsion is formed by bulk emulsification.

[0015] In some embodiments, the hydrocarbon solvent is selected from the group consisting of dichloromethane, chloroform, toluene, ethyl acetate, tetrahydrofuran, or a combination thereof.

[0016] In some embodiments, the fluorocarbon solution contains 1,1,2,2,3,3,4,4,4-nonafluoro-N,N-bis(1,1,2,2,3,3,4,4,4-nonafluorobutyl)butan-1-amine.

[0017] In some embodiments, the fluorinated surfactant is perfluoropolyether-β-polyethylene glycol-β-perfluoropolyether. Some embodiments have a fluorinated surfactant concentration of 0.1 to 5.0% w / v, typically about 0.5% w / v.

[0018] In some embodiments, the hydrofluoroester is 2-(trifluoromethyl)-3-ethoxidedecafluorohexane.

[0019] In some embodiments, the protein powder to polymer ratio is 0% to 30%.

[0020] In some embodiments, the porous membrane is a stainless steel membrane, and optionally, a fluorine-coated stainless steel membrane.

[0021] Fluorocarbons and hydrocarbon liquids can be removed by evaporating them under ambient atmospheric pressure or vacuum. In some embodiments, the fluorocarbon liquid contains hydrofluoroether (HFE). In some embodiments, HFE is added to a non-aqueous emulsion to rapidly extract hydrocarbons into the fluorocarbon liquid and accelerate microsphere curing. In some embodiments, the protein powder is micronized protein powder. In some embodiments, the fine particles are washed to remove any residual hydrocarbon solvents, fluorocarbon liquids, fluorinated surfactants, or combinations thereof remaining on the fine particles. Exemplary fluorocarbon liquids include, but are not limited to, perfluoro C5-C18 compounds, such as 1,1,2,2,3,3,4,4,4-nonafluoro-N,N-bis(1,1,2,2,3,3,4,4,4-nonafluorobutyl)butan-1-amine. Exemplary hydrocarbon solvents include, but are not limited to, dichloromethane, chloroform, ethyl acetate, and combinations thereof. An exemplary fluorinated surfactant is perfluoropolyether-b-polyethylene glycol-b-perfluoropolyether (PFPE-PEG-PFPE) triblock copolymer. An exemplary bio-erosive polymer is polyorthoester (POE). In some embodiments, the protein is an antibody or its antigen-binding fragment, fusion protein, or recombinant protein. In some embodiments, the protein is a spray-dried VEGF trap protein. In some embodiments, the microparticles have a diameter of 1.0–100 μm, 1.0–200 μm, or 30–60 μm. In some embodiments, the microparticles formed by the disclosed non-aqueous emulsion method are a fluid microparticle composition. The disclosed fluid microparticle composition can be suspended in a pharmaceutically acceptable excipient, such as pH-buffered saline, or in an oily vehicle such as a medium-chain triglyceride. The fluid microparticle composition can be administered parenterally, for example, using a syringe having a 27G needle. In some embodiments, the microsphere or microparticle size distribution is less than 10 CV%.In some embodiments, the microsphere size distribution is 10 - 20 CV%.

[0022] Another embodiment involves combining 1.0 - 30% w / w of a total solid spray - dried protein in a hydrocarbon solution to form a first non - aqueous solution, stirring the first non - aqueous solution to form a suspension, and feeding the suspension to a dispersion cell, wherein the suspension is injected into a continuous phase containing a fluorocarbon liquid and 0.1 - 5.0% w / v of a fluorinated surfactant through a porous membrane under a counter - current flow of the continuous phase to form a hydrocarbon emulsion in fluorocarbon, feeding, removing the hydrocarbon solvent to provide a cured polymer or a polymer - coated microsphere, and removing the fluorocarbon liquid to isolate the microparticles, wherein the microparticles contain a protein encapsulated within a polymer matrix, thereby providing a method for manufacturing polymer or polymer - coated microparticles. In some embodiments, the feeding of the suspension is at a rate of 0.1 - 1.0 ml / min. In some embodiments, the method further includes adding a hydrofluoroester as a co - solvent to the fluorocarbon liquid of the hydrocarbon emulsion in fluorocarbon to extract the hydrocarbon solvent from the dispersed phase to the continuous phase and assist in accelerating the curing of the microparticles.

[0023] In some embodiments, the microparticles produced by the membrane emulsion have few or no pores or channels in the polymer surface or internal matrix of the microparticles.

[0024] Yet another embodiment provides a pharmaceutical composition containing polymer - coated microparticles produced using the non - aqueous membrane emulsion method disclosed herein.

[0025] In some embodiments, the size of the microparticles can be adjusted to a desired diameter or size by varying the formulation composition and process parameters. BRIEF DESCRIPTION OF THE DRAWINGS

[0026] [Figure 1A] Figure 1A is a diagram showing the process of manufacturing blank POE microspheres via an H / F-based bulk emulsion (Scheme 1). [Figure 1B] Figure 1B shows the chemical structure of FC-40. [Figure 1C] Figure 1C shows the chemical structure of the fluorosurfactant PFPE-PEG-PFPE (Pico-Surf™ 1), which is a perfluoropolyether / poly(ethylene glycol) triblock copolymer. Pico-Surf™ 1 is commercially available, for example, at 5% (w / w) in FC-40. [Figure 2] Figure 2A is a micrograph of blank POE microspheres formed via an H / F emulsion. Figure 2B is a micrograph showing POE aggregation found at low FS content. [Figure 3] Figures 3A, 3B, and 3C are micrographs of blank POE microspheres formed via H / F emulsions having low, medium, and high homogenization rates. [Figure 4] Figure 4 (Scheme 2) is a diagram showing the process of SDP encapsulation in POE microspheres via an S / H / F-based bulk emulsion. [Figure 5] Figure 5 (Scheme 3) is a diagram showing a hydrocarbon emulsion system in fluorocarbon for the encapsulation of protein SDP. [Figure 6] Figures 6A and 6B are fluorescence images of ethyl acetate droplets containing POE and fluorescently labeled spray-dried protein (F-SDP) dispersed in FC-40. Note that F-SDP retains its original size and morphology within the droplets. The green fluorescence image is represented in grayscale. [Figure 7]Figure 7A is a bright-field microscope image of VEGF-trapped F-SDP-encapsulated microspheres. Figure 7B is a fluorescence image of VEGF-trapped F-SDP-encapsulated microspheres (bar = 20 μm). Figure 7C is a fluorescence image of VEGF-trapped F-SDP-encapsulated microspheres (bar = 10 μm). The green fluorescence image is shown in grayscale in Figures 7B and 7C. [Figure 8] Figures 8A–8D are fluorescence images of VEGF-trapped F-SDP-encapsulated POE microspheres placed in an aqueous environment. Note that the F-SDP retains its original size and shape within the droplet. The green fluorescence images are shown in grayscale. [Figure 9] Figure 9 is a line graph showing the volume density (%) versus size (μm) of fine particles produced using dichloromethane (DCM) or ethyl acetate (EtAc) in a non-aqueous emulsion method. [Figure 10] Figures 10A and 10B are micrographs of microparticles packed with 10% and 30% w / w VEGF-trapped SDP, respectively. [Figure 11] Figures 11A and 11B are representative fluorescence images of VEGF-trapped F-SDP-encapsulated POE microspheres filled with 10% and 30% w / w SDP, respectively. Note that the F-SDP retains its original size and shape within the droplet. The green fluorescence images are shown in grayscale. [Figure 12] Figures 12A and 12B are scanning electron microscope (SEM) images of microparticles filled with 5% w / w SDP and 10% w / w SDP, respectively. [Figure 13] Figures 13A and 13B are SEM images of spray-dried proteins with Dv50 values ​​of 2.18 μm and 5.63 μm, respectively. [Figure 14] Figures 14A, 14B, and 14C are bright-field, fluorescence, and SEM images of VEGF-trapped F-SDP encapsulated in PLA microspheres. The green fluorescence image is shown in grayscale in Figure 14B. [Figure 15]Figures 15A and 15B are bright-field and fluorescence images of VEGF-trapped F-SDP enclosed in PLGA microspheres. The green fluorescence image is shown in grayscale in Figure 15B. [Figure 16] Figure 16 shows the formation of SDP suspension emulsion droplets when the suspension is injected into a continuous hydrocarbon phase through a porous membrane. [Figure 17] Figure 17 is a diagram illustrating an exemplary method for producing microparticles using a membrane emulsion. Steps marked with stars indicate steps to prevent flocculation and aggregation of the microparticle product. [Figure 18] Figure 18 includes SEM images of microspheres produced using aqueous and non-aqueous emulsion methods, showing that the microspheres produced using the non-aqueous method have a smooth surface, while those produced using the aqueous method have pores and water channels. [Figure 19-1] Figure 19 includes SEM images of protein-encapsulated microspheres prepared using aqueous and non-aqueous emulsion methods. [Figure 19-2] Figure 19 includes SEM images of protein-encapsulated microspheres prepared using aqueous and non-aqueous emulsion methods. [Figure 20] Figure 20 includes fluorescence microscopy images of protein-encapsulated microspheres prepared using aqueous and non-aqueous emulsion methods, showing that the SDP was reconstituted and fused into larger droplets using the aqueous emulsion method, while the original raisin shape was retained using the non-aqueous emulsion method. The green fluorescence image is represented in grayscale. [Modes for carrying out the invention]

[0027] I. Definition The compositions and methods described herein, as well as the experimental conditions described herein, are subject to change, and therefore this disclosure is not limited thereto. Furthermore, the scope of this disclosure is limited only by the appended claims, and the terms used herein are for illustrative purposes only and are not intended to limit any particular embodiment.

[0028] Unless otherwise defined, all technical and scientific terms used herein have the same meanings as those generally understood by those skilled in the art to which this disclosure pertains. Any compositions, methods, and materials similar or equivalent to those described herein may be used in carrying out or testing the present invention. All publications mentioned herein are incorporated herein in their entirety by reference.

[0029] In the context of describing the invention described in these claims (particularly in the context of the claims), the use of the terms “a,” “an,” “the,” and similar referents should be interpreted to encompass both singular and plural forms, unless otherwise indicated herein or the context clearly contradicts this interpretation.

[0030] All numerical limits and ranges shown herein include all numerical values ​​or values ​​that fall around or between the numerical values ​​of the range or limit. The ranges and limits described herein explicitly represent and describe all integers, decimals, and fractional values ​​defined and encompassed by the range or limit. Accordingly, the enumeration of ranges of values ​​herein is intended only as a simplified way of referring individually to each separate value contained within a range, unless otherwise indicated herein, and each separate value is incorporated herein as if it were individually enumerated herein.

[0031] The use of the term “about” is intended to represent values ​​that are approximately + / - 10% above or below the stated values; in other embodiments, the values ​​may be in a range of approximately + / - 5% above or below the stated values; in other embodiments, the values ​​may be in a range of approximately + / - 2% above or below the stated values; and in other embodiments, the values ​​may be in a range of approximately + / - 1% above or below the stated values. The aforementioned ranges are intended to be clarified by context and are not implied to be further limited. All methods described herein may be carried out in any preferred order unless otherwise indicated herein or unless it is clearly inconsistent by context. Any and all embodiments provided herein, or the use of exemplary language (e.g., “etc.”), are merely intended to better illustrate the invention and do not limit the scope of the invention unless otherwise stated in the claims. Nothing in this specification should be construed as indicating that any element not described in the claims is essential for carrying out the invention.

[0032] "Formulating" provides forming forces, including compressive shear forces and cavitation. Techniques and methods include, but are not limited to, homogenization, vortexing, sonication, stirring, churning, whisking, shaking, emulsification, agitation, and / or combinations thereof. The application of forming forces may be constant or periodic.

[0033] The terms "microspheres" and "particles" are used interchangeably.

[0034] A "protein" refers to a molecule containing two or more amino acid residues joined to each other by peptide bonds. Proteins include polypeptides and peptides, and may also include modifications such as glycosylation, lipid attachment, sulfated molecules, gamma-carboxylation, alkylation, hydroxylation, and ADP-ribosylation of glutamate residues. Proteins may be of scientific or commercial interest, including protein-based drugs, and examples of proteins include, among others, enzymes, ligands, receptors, antibodies, and chimeric or fusion proteins. Proteins are produced by various types of recombinant cells using well-known cell culture methods and are generally introduced into cells by genetic engineering techniques (e.g., sequences encoding chimeric proteins, or codon-optimized sequences, intron-less sequences, etc.), which may exist as episomes or be incorporated into the cell's genome.

[0035] An "antibody" refers to an immunoglobulin molecule consisting of four polypeptide chains interconnected by disulfide bonds: two heavy (H) chains and two light (L) chains. Each heavy chain has a heavy chain variable region (HCVR or VH) and a heavy chain constant region. The heavy chain constant region contains three domains: CH1, CH2, and CH3. Each light chain has a light chain variable region and a light chain constant region. The light chain constant region consists of one domain (CL). The VH and VL regions can be further subdivided into hypervariable regions called complementarity-determining regions (CDRs), which are dotted with more conserved regions called framework regions (FRs). Each VH and VL consists of three CDRs and four FRs arranged from the amino terminus to the carboxyl terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The term "antibody" includes references to both glycosylated and nonglycosylated immunoglobulins of any isotype or subclass. The term “antibody” includes antibody molecules prepared, expressed, produced, or isolated by recombinant means, such as antibodies isolated from host cells transfected to express antibodies. The term “antibody” also includes bispecific antibodies containing heterotetrameric immunoglobulins capable of binding to two or more different epitopes. Bispecific antibodies are generally described in U.S. Patent No. 8,586,713 (incorporated herein by reference).

[0036] An "Fc fusion protein" comprises part or all of two or more proteins (one of which is the Fc portion of an immunoglobulin molecule, otherwise not found together in nature). For the preparation of fusion proteins containing specific heterologous polypeptides fused to various portions of antibody-derived polypeptides (including the Fc domain), see, for example, Ashkenazi et al., Proc. Natl. Acad. Sci. USA 88:10535, 1991; Byrn et al., Nature 344:677, 1990; and Hollenbaugh et al., “Construction of Immunoglobulin Fusion Proteins”, in Current Protocols in Immunology, Suppl. 4, pages 10.19.1-10.19.11, 1992. A "receptor Fc fusion protein" comprises one or more extracellular domains of a receptor ligated to the Fc portion, which in some embodiments include a hinge region followed by the CH2 and CH3 domains of the immunoglobulin. In some embodiments, the Fc fusion protein comprises two or more distinct receptor chains that bind to one or more ligands. For example, the Fc fusion protein is a trap, such as an IL-1 trap or a VEGF trap.

[0037] Recombinantly produced enzymes and proteins lacking the Fc moiety, such as minitraps, can also be produced according to the present invention. Minitraps are trap proteins that use a polymerizing component (MC) instead of the Fc moiety and are disclosed in U.S. Patents 7,279,159 and 7,087,411.

[0038] "Micronized protein particles" or "protein particles" means particles containing multiple molecules of protein with low, very low, or near-zero amounts of water (e.g., less than 3% by weight of water). As used herein, micronized protein particles are generally spherical and have an ECD ranging from 2 microns to about 35 microns. Micronized protein particles are not limited to any particular protein entity and are suitable for the preparation and delivery of therapeutic proteins. Common therapeutic proteins include, among others, soluble receptor fragments, antibodies (including IgG) and derivatives or fragments of antibodies, other Fc-containing proteins including Fc fusion proteins, and receptor-Fc fusion proteins including trap-type proteins such as VEGF traps (Huang, C., Curr. Opin. Biotechnol. 20:692-99 (2009)).

[0039] II. Production of particulate formulations using hydrocarbon-fluorocarbon membrane emulsions Systems and methods are provided for formulating pharmaceutical compositions using anhydrous or non-aqueous membrane emulsion systems. The disclosed anhydrous membrane emulsion methods overcome several problems of existing aqueous emulsion systems when encapsulating hydrophilic drug molecules. For example, comparative studies of the disclosed anhydrous emulsion systems and existing aqueous emulsion systems provided herein show that formulations produced using aqueous emulsion systems leak drugs, such as protein drugs, from the emulsion droplets into the aqueous continuous phase during production. This leakage of drugs from the emulsion droplets results in low encapsulation efficiency. The non-aqueous-based membrane emulsion methods disclosed herein encapsulate drug molecules, including but not limited to hydrophilic drugs such as proteins, with increased encapsulation efficiency compared to aqueous emulsion systems, while preserving the original protein particle structure, or a combination thereof. The disclosed anhydrous membrane emulsion systems and methods can be used to produce drug formulations encapsulated by bulk methods (e.g., stirring, homogenization, sonication) and other conventional methods. The systems and methods can also be applied to a wide range of polymer materials, solid payloads, and emulsification methods. The following summary presents the results of a comparison of different emulsion takes, demonstrating that the non-aqueous emulsion system offers a significant improvement in particulate encapsulation compared to the aqueous emulsion system. [Table 1]

[0040] A. Solid (S / H / F) film emulsion in fluorocarbons and hydrocarbons Membrane emulsification (ME) is a relatively new technique for the highly controlled production of particles, generally enabling good size control and a narrow size distribution (GTVladisavljevic and RAWilliams, Adv. Colloid Interface Sci., vol.113(1):1-20, (2005)). To date, many types of membranes have been developed for ME, including Shirasu Porous Glass (SPG), cellulose acetate, polymers, anodic porous alumina, and silicon microchannels. For the disclosed ME method, stainless steel membranes with laser-drilled pores have performed well, and commercially available equipment from Micropore Technologies (Redcar, UK) has enabled laboratory research processes and scale-up to GMP production. In other embodiments, the membrane is selected from the group consisting of Shirasu Porous Glass (SPG), cellulose acetate, polymers, anodic porous alumina, and silicon microchannels. The tightly controlled pore size of the stainless steel membrane ensures that all SDP particles below the limit pass through the membrane. The straight, tubular channels, without winding paths, reduce the tendency for channel blockage by SDPs. In some embodiments, the membrane has a fluorophilic coating that provides good compatibility with the production of hydrocarbon (H / F) emulsions in fluorocarbons. Furthermore, the stainless steel membrane is robust, easy to clean, and sterilizable. In some embodiments, the pore diameter is 3 μm to 300 μm. In some embodiments, the pore diameter is 10, 15, 20, 25, 30, 35, 40, 45, or 50 μm.

[0041] Several embodiments provide a method for producing sustained-release or controlled-release microparticles by combining pulverized protein powder and polymer in a hydrocarbon solvent to form a first non-aqueous solution, stirring the first non-aqueous solution to form a suspension, and supplying the suspension into a dispersion pump, wherein the suspension is injected through a porous membrane into a continuous phase containing a fluorocarbon liquid and a fluorinated surfactant to form a hydrocarbon emulsion in a fluorocarbon. In some embodiments, the suspension is supplied at a rate of 0.1 to 1.0 ml / min. The method further comprises the steps of adding a hydrofluoroester to the hydrocarbon emulsion in a fluorocarbon and removing the hydrocarbon solvent to provide cured microparticles. In some embodiments, a mixture of the hydrofluoroester and fluorocarbon is added to the emulsion. In some embodiments, the method includes adding an additional pure hydrofluoroester to the emulsion. The method further comprises removing the fluorocarbon liquid to isolate the microparticles, which contain proteins encapsulated within a polymer matrix. This method optionally includes washing the microparticles in the fluorocarbon liquid to remove residual fluorinated surfactants, removing the fluorocarbon liquid, and collecting the microparticles by, for example, vacuum filtration. In some embodiments, a polyethersulfone membrane filter is used for vacuum filtration. In some embodiments, the protein powder is prepared from an antibody or its antigen-binding fragment, fusion protein, or recombinant protein. In some embodiments, the protein is a VEGF trap protein, such as aflibercept. In some embodiments, the emulsion is formed by a bulk emulsion. In some embodiments, the microparticles have a burst of less than 15% after 24 hours, followed by a linear sustained release of the drug.

[0042] In some embodiments, the protein powder to polymer ratio is 0% to 30%.

[0043] In some embodiments, the hydrocarbon solvent is selected from the group consisting of dichloromethane, chloroform, toluene, ethyl acetate, tetrahydrofuran, or a combination thereof.

[0044] In some embodiments, the fluorocarbon solution contains 1,1,2,2,3,3,4,4,4-nonafluoro-N,N-bis(1,1,2,2,3,3,4,4,4-nonafluorobutyl)butan-1-amine.

[0045] In some embodiments, the fluorinated surfactant is perfluoropolyether-b-polyethylene glycol-b-perfluoropolyether.

[0046] In some embodiments, the hydrofluoroester is 2-(trifluoromethyl)-3-ethoxidedecafluorohexane.

[0047] In some embodiments, the porous membrane is a stainless steel membrane, and optionally, a fluorine-coated stainless steel membrane.

[0048] Fluorocarbons and hydrocarbon liquids can be removed by evaporating them under ambient atmospheric pressure or vacuum. In some embodiments, the fluorocarbon liquid contains hydrofluoroether (HFE). In some embodiments, HFE is added to a non-aqueous emulsion to rapidly extract hydrocarbons into the fluorocarbon liquid and accelerate microsphere curing. In some embodiments, the protein powder is micronized protein powder. In some embodiments, the fine particles are washed to remove any residual hydrocarbon solvents, fluorocarbon liquids, fluorinated surfactants, or combinations thereof remaining on the fine particles. Exemplary fluorocarbon liquids include, but are not limited to, perfluoro C5-C18 compounds, such as 1,1,2,2,3,3,4,4,4-nonafluoro-N,N-bis(1,1,2,2,3,3,4,4,4-nonafluorobutyl)butan-1-amine. Exemplary hydrocarbon solvents include, but are not limited to, dichloromethane, chloroform, ethyl acetate, and combinations thereof. An exemplary fluorinated surfactant is perfluoropolyether-b-polyethylene glycol-b-perfluoropolyether (PFPE-PEG-PFPE) triblock copolymer. An exemplary bio-erosive polymer is polyorthoester (POE). In some embodiments, the protein is an antibody or its antigen-binding fragment, fusion protein, or recombinant protein. In some embodiments, the protein is a spray-dried VEGF trap protein. In some embodiments, the microparticles have a diameter of 1.0–100 μm, 1.0–200 μm, or 30–60 μm. In some embodiments, the microparticles formed by the disclosed non-aqueous emulsion method are a fluid microparticle composition. The disclosed fluid microparticle composition can be suspended in a pharmaceutically acceptable excipient, such as pH-buffered saline, or in an oily vehicle such as a medium-chain triglyceride. The fluid microparticle composition can be administered parenterally, for example, using a syringe having a 27G needle. In some embodiments, the microsphere or microparticle size distribution is less than 10 CV%%.In some embodiments, the microsphere size distribution is 10–20 CV%.

[0049] Another embodiment provides a method for producing polymers or polymer-coated microparticles by combining 1-30% w / w all-solid spray-dried proteins in a hydrocarbon solution to form a first non-aqueous solution; stirring the first non-aqueous solution to form a suspension; supplying the suspension to a dispersion pump, which injects the suspension into a continuous phase containing a fluorocarbon liquid and 0.1-5.0% w / v fluorinated surfactant via a porous membrane under contiguous flow of the continuous phase to form a hydrocarbon emulsion in a fluorocarbon; removing the hydrocarbon solvent to provide a cured polymer or polymer-coated microspheres; and removing the fluorocarbon liquid to isolate the microparticles, wherein the microparticles contain proteins encapsulated within a polymer matrix. In some embodiments, the method further includes the step of adding a hydrofluoroester to the fluorocarbon liquid of the hydrocarbon emulsion in a fluorocarbon before removing the hydrocarbon solvent to assist in the removal of the hydrocarbon solvent.

[0050] In some embodiments, the microparticles produced by the film emulsion have little to no pores or channels in the polymer surface or internal matrix of the microparticles.

[0051] Yet another embodiment provides a pharmaceutical composition containing polymer-coated microparticles prepared using the non-aqueous film emulsion method disclosed herein.

[0052] In some embodiments, the size of the particles can be adjusted to a desired diameter or size by changing the formulation composition and process parameters.

[0053] Hydrocarbon and protein solutions can be formed by applying compounding forces such as compressive shear and cavitation. Techniques include, but are not limited to, homogenization, vortexing, sonication, stirring, churning, whisking, shaking, emulsification, stirring, and / or combinations thereof. The method further includes the step of removing the hydrocarbon solvent and fluorocarbon liquid while stirring the emulsion. The hydrocarbon and fluorocarbon liquids may optionally be removed by evaporation under vacuum. In other embodiments, the fine particles may be collected by filtration. The fine particles are cured by removing the hydrocarbon and fluorocarbon liquids, and then the fine particles can be collected. In some embodiments, HFE can be added to the fluorocarbon to extract hydrocarbons from the dispersed phase into the fluorocarbon continuous phase, thereby assisting in obtaining a faster curing process. HFE is miscible with both fluorocarbons and hydrocarbons and can therefore act as a co-solvent to increase the solubility of hydrocarbons in the fluorocarbon phase. The sustained-release fine particles produced by the non-aqueous emulsion method contain proteins encapsulated within a matrix of biodegradable or bio-erosive polymers. In some embodiments, the microparticles have a single-core-shell structure. In other embodiments, the microparticles have multiple cores dispersed within the polymer. In yet another embodiment, the collection of microparticles includes microparticles having a single-core structure encapsulated by a polymer surface and microparticles having a multi-core structure within the polymer surface. The fluorocarbon liquid may be a perfluoro C5-C18 compound, including but not limited to FC-40, and the hydrocarbon solution may be selected from ethyl acetate, chloroform, toluene, ethyl acetate, tetrahydrofuran, and dichloromethane or a combination thereof. In some embodiments, the fluorinated surfactant is perfluoropolyether-β-polyethylene glycol-β-perfluoropolyether, commercially available as Pico-Surf® 1. In some embodiments, the bio-erosive polymer is POE. In other embodiments, the polymer may be selected from the group consisting of polylactic acid and poly(lactic acid-coglycolic acid).Generally, proteins are antibodies or their antigen-binding fragments, fusion proteins, recombinant proteins, or fragments or cleaved versions thereof. Typically, proteins are micronized by, for example, spray drying, electrospray drying, reversible precipitation, spray freezing, microtemplates, or a combination thereof. In some embodiments, the protein is a VEGF trap protein or a cleaved form thereof. Other proteins that may be used in the disclosed method are listed below. The microparticles produced by the disclosed method have a polymer surface that is largely devoid of pores or channels. The polymer surface is not perforated. In some embodiments, the microparticles have a diameter of 1 to 200 μm.

[0054] 1. Hydrocarbon solvents In some embodiments, the hydrocarbon solvent (also called hydrocarbon liquid) is selected such that the polymer material, for example, a biodegradable or bioerosive polymer, is soluble in the hydrocarbon. In some embodiments, the hydrocarbon solvent is selected from the group consisting of dichloromethane, chloroform, toluene, ethyl acetate, tetrahydrofuran, or combinations thereof. In some embodiments, the hydrocarbon solvent may include acetonitrile, dimethylformamide, dimethyl sulfoxide, acetone, ethanol, methanol, pentane, propanol, hexane, or combinations thereof.

[0055] 2. Fluorine-based liquids Exemplary fluorinated liquids include, but are not limited to, fluorocarbon liquids such as Fluorinert® FC-40 (average MW = 650 g / mol), 1,1,2,2,3,3,4,4,4-nonafluoro-N,N-bis(1,1,2,2,3,3,4,4,4-nonafluorobutyl)butane-1-amine (Figure 1B), Fluorinert® FC-70 (average MW = 821 g / mol), or combinations thereof. In some embodiments, the fluorocarbon liquid is or contains a hydrofluoroether (HFE). Examples of HFEs include, but are not limited to, NOVEC® 7000 (1-methoxyheptafluoropropane), NOVEC® 7100 (methoxy-nonafluorobutane), NOVEC® 7200 (ethoxy-nonafluorobutane), and NOVEC® 7500 (2-(trifluoromethyl)-3-ethoxide dodecafluorohexane). In further embodiments, the fluorocarbon liquid may be FC-40, FC-70, Novec® 7500, Novec® 7100, Novec It contains c(trademark)7000, or a combination thereof. In certain embodiments, the second solution contains a fluorinated surfactant (FS) in addition to the fluorinated liquid. An exemplary FS is perfluoropolyether-b-polyethylene glycol-b-perfluoropolyether (PFPE-PEG-PFPE) triblock copolymer, which is commercially available as Pico-Surf(trademark)1. In some embodiments, the fluorocarbon liquid or the second solution contains FC-40 and Pico-Surf(trademark)1.

[0056] In some embodiments, FS is [ka] In the equation, n is approximately 37, x+z is approximately 6.0, and y is approximately 12.5, or n=3.7, x+z is approximately 3.6, and y is approximately 9.0 (Lee, M. et al., Lab Chip., 7:14(3):509-13(2014)).

[0057] In some embodiments, HFE has the following chemical structure: [ka]

[0058] Other HFEs suitable for process use are a class of molecules in which all hydrogen atoms are present on the carbon without fluorine substitution and are separated from the fluorinated carbon by ether oxygen, i.e., RfORh. HFEs can be linear, branched, cyclic, or a combination thereof (e.g., alkylcyclic aliphatic), preferably free of ethylene-based unsaturated atoms, and have a molecular structure with a total of about 4 to about 20 carbon atoms. Such HFEs are known and readily available as essentially pure compounds or mixtures. Due to their lipophilic and fluorophilic properties, HFEs are miscible with both fluorocarbons and hydrocarbons. When added to hydrocarbon / fluorocarbon emulsions, they can act as a co-solvent to extract hydrocarbons into the fluorocarbon phase and accelerate the curing process.

[0059] In some embodiments, the hydrocarbon solvent, fluorocarbon, or both are optionally removed by evaporation under vacuum while the emulsion is optionally stirred. In some embodiments, particulate matter is collected by filtration, optionally by filtration under vacuum.

[0060] The percentage of HFE in the fluorocarbon phase can be 0-20% v / v, while increasing the HFE percentage increases the hydrocarbon extraction rate. However, the HFE percentage should not be too high, as this can make it more difficult to control the size and morphology of the microspheres.

[0061] 3. Corrosive or biodegradable polymers In some embodiments, the polymer is a biodegradable or bio-erosive polymer. In some embodiments, the polymer is branched or linear polyethylene glycol (PEG), polylactic acid (PLA), polyglycolic acid (PGA), polylactic acid-polyglycolic acid copolymer (PLGA), poly-d,l-lactide-coglycolide (PLGA), PLGA-ethylene oxide fumarate, PLGA-alpha-tocopheryl succinate esterified with polyethylene glycol 1000 (PLGA-TGPS), polyanhydride poly[1,6-bis(p-carboxyphenoxy)hexane] (pCPH), Poly(hydroxybutyrate-cohydroxyvaleric acid) (PHB-PVA), polyethylene glycol-poly(lactic acid) copolymer (PEG-PLA), poly-ε-caprolactone (PCL), poly-alkyl-cyanoacrylate (PAC), poly(ethyl)cyanoacrylate (PEC), polyisobutylcyanoacrylate, poly-N-(2-hydroxypropyl)methacrylamide (Poly(HPMA)), poly-β-R-hydroxybutyrate (PHB), poly-β-R-hydroxyalkanoate (PHA), poly-β -R-malic acid, phospholipid-cholesterol polymer, 2-dioleoyl-sn-glycero-3-phosphatidylcholine / polyethylene glycol-distearoylphosphatidylethanolamine (DOPC / PEG-DSPE) / cholesterol, polysaccharides, cellulose, ethylcellulose, methylcellulose, alginate, dextran and dextran hydrogel polymer, amylose, inulin, pectin and guar gum, chitosan, chitin, heparin, hyaluronic acid, cyclodextrin (CD) based polymer The following are selected from the group consisting of lilotaxanes and polypsotaxanes, polyaspartates, polyglutamates, polylucins, leucine-glutamate copolymers, polybutylene succinates, gelatin, collagen, fibrin, fibroin, polyorthoesters, polyorthoester-polyamidine copolymers, polyorthoester-diamine copolymers, polyorthoesters incorporating latent acids, poly(ethylene glycol) / poly(butylene terephthalate) copolymers, and combinations and copolymers thereof.In some embodiments, the polymer is poly-ε-caprolactone (PCL) or its derivatives or copolymers. In some embodiments, the polymer is PLGA or its derivatives or copolymers. In some embodiments, the polymer is ethylcellulose or its derivatives or copolymers. In some embodiments, the polymer is polyorthoester or its derivatives or copolymers. In some embodiments, the polymer is polyesteramide.

[0062] As used herein, the term “polymer” refers to a macromolecule containing repeating monomers linked by covalent chemical bonds. Polymers are biocompatible and biodegradable. Biocompatible and biodegradable polymers may be natural or synthetic. Natural polymers include polynucleotides, polypeptides, e.g., naturally occurring proteins, recombinant proteins, gelatin, collagen, fibrin, fibroin, polyaspartate, polyglutamate, polylysine, leucine-glutamate copolymers, and polysaccharides, e.g., cellulose alginate, dextran and dextran hydrogel polymers, amylose, inulin, pectin and guar gum, chitosan, chitin, heparin and hyaluronic acid.Examples of synthetic biocompatible or biodegradable polymers include polylactic acid (PLA), polyglycolic acid (PGA), polylactic acid-polyglycolic acid copolymer (PLGA), poly-d,l-lactide-coglycolide (PLGA), PLGA-ethylene oxide fumarate, PLGA-alpha-tocopheryl succinate esterified with polyethylene glycol 1000 (PLGA-TGPS), polyanhydride poly[1,6-bis(p-carboxyphenoxy)hexane] (pCPH), poly(hydroxybutyrate-cohydroxyvaleric acid) (PHB-PVA), polyethylene glycol-poly(lactic acid) copolymer (PEG-PLA), poly-ε-caprolactone (PCL), poly-alkyl-cyanoacrylate (PAC), poly(ethyl)cyanoacrylate (PEC), and poly Examples include isobutylcyanoacrylate, poly-N-(2-hydroxypropyl)methacrylamide (poly(HPMA)), poly-β-R-hydroxybutyrate (PHB), poly-β-R-hydroxyalkanoate (PHA), poly-β-R-malic acid, phospholipid-cholesterol polymers, 2-dioleoyl-sn-glycero-3-phosphatidylcholine / polyethylene glycol-distearoylphosphatidylethanolamine (DOPC / PEG-DSPE) / cholesterol, ethylcellulose, cyclodextrin (CD)-based polyrotaxanes and polypserotaxanes, polybutylene succinate (PBS), polyorthoesters, polyorthoester-polyamidine copolymers, polyorthoester-diamine copolymers, polyorthoesters incorporating latent acids to control rates of degradation, and, in particular, poly(ethylene glycol) / poly(butylene terephthalate) copolymers.

[0063] Ethylcellulose (EC) is a well-known and readily available biomaterial used in pharmaceutical and food science. It is a cellulose derivative in which some glucose hydroxyl groups are replaced with ethyl ether. For a method of using ethylcellulose as a biocompatible polymer in the production of microspheres, see Martinac et al., J. Microencapsulation, 22(5):549-561 (2005) and its references. For a detailed description of methods for producing ethylcellulose and its derivatives, see U.S. Patent No. 4,210,529 (1980) and its references.

[0064] Poly-d,l-lactide-coglycolide (PLGA) is also a well-known, FDA-approved, biocompatible and biodegradable polymer used in tissue engineering and drug delivery systems. PLGA is a polyester containing glycolic acid and lactic acid monomers. For a description of PLGA synthesis and the production of PLGA nanoparticles, see Astete and Sabliov, Biomator. Sci. Polym. Ed., 17(3):247-89 (2006) and its references.

[0065] Poly-ε-caprolactone (PCL) is another biocompatible and biodegradable polymer approved by the FDA for use in humans as a drug delivery device. PCL is a polyester of ε-caprolactone that rapidly hydrolyzes in the body to form non-toxic or low-toxicity hydroxycarboxylic acids. For a description of the manufacture of PCL, see Labet and Thielemans, Chemical Society Reviews 38:3484-3504 (2009) and its references. For a description of the manufacture and use of PCL-based microspheres and nanospheres as delivery systems, see Sinha et al., Int. J. Pharm., 278(1):1-23 (2004) and its references.

[0066] Polyorthoesters (POEs) are bio-erosive polymers designed for drug delivery. Generally, they are polymers of ketene acetals, preferably cyclic diketene acetals, such as 3,9-dimethylene-2,4,8,10-tetraoxaspiro[5.5]-undecane, which polymerize by glycol condensation to form orthoester bonds. Descriptions of polyorthoester synthesis and various types can be found, for example, in U.S. Patent No. 4,304,767. Polyorthoesters can be modified to control their drug release profiles and degradation rates by substituting various hydrophobic diols and polyols, such as replacing hexanetriol with decantriol, and by adding potential acids, such as glycolide and octanodioic acid, to the backbone to increase pH sensitivity. Custom forms of POEs may contain glycolic acid in the POE backbone to modulate mass loss and drug release. Other modifications to polyorthoesters include the incorporation of amines to increase functionality. The formation, description, and use of polyorthoesters are described in U.S. Patent No. 5,968,543, U.S. Patent No. 4,764,364, Heller and Barr, Biomacromolecules, 5(5):1625-32 (2004), and Heller, Adv. Drug. Deliv. Rev., 57:2053-62 (2005).

[0067] 4. Protein drugs In some embodiments, the particulate formulations produced by the disclosed anhydrous emulsion methods and systems include drugs. Exemplary drugs include, but are not limited to, proteins, fusion proteins and their fragments, antibodies and their antigen-binding fragments, and ligand-binding domains and proteins. In some embodiments, the protein is a VEGF trap protein (e.g., aflibercept), which contains the Ig domain 2 of the VEGF receptor Flt1 fused to the Ig domain 3 of the VEGF receptor Flk1 fused to the Fc of hIgG1, as described, for example, U.S. Patents 7,087,411 and 7,279,159 (both incorporated herein by reference). In some embodiments, the VEGF trap protein is a cleaved form of a VEGF trap, as described in U.S. Patent 7,396,664 (both incorporated herein by reference).

[0068] In some embodiments, the protein in the microparticle formulation is an antibody, human antibody, humanized antibody, chimeric antibody, monoclonal antibody, multispecific antibody, bispecific antibody, antigen-binding antibody fragment, single-chain antibody, diabody, triabody or tetrabody, a bispecific tetravalent immunoglobulin G-like molecule called bivariable domain immunoglobulin (DVD-IG), IgD antibody, IgE antibody, IgM antibody, IgG antibody, IgG1 antibody, IgG2 antibody, IgG3 antibody, or IgG4 antibody. In some embodiments, the antibody is an IgG1 antibody. In some embodiments, the antibody is an IgG2 antibody. In some embodiments, the antibody is an IgG4 antibody. In some embodiments, the antibody contains a chimeric hinge. In yet other embodiments, the antibody contains a chimeric Fc. In some embodiments, the antibody is a chimeric IgG2 / IgG4 antibody. In some embodiments, the antibody is a chimeric IgG2 / IgG1 antibody. In some embodiments, the antibody is a chimeric IgG2 / IgG1 / IgG4 antibody.

[0069] In some embodiments, the antibodies include anti-programmed cell death 1 antibody (e.g., anti-PD1 antibody as described in U.S. Patent No. 9,987,500), anti-programmed cell death ligand-1 (e.g., anti-PD-L1 antibody as described in U.S. Patent No. 9,938,345), anti-Dll4 antibody, anti-angiopoietin-2 antibody (e.g., anti-ANG2 antibody as described in U.S. Patent No. 9,402,898), anti-angiopoietin-like 3 antibody (e.g., anti-AngPtl3 antibody as described in U.S. Patent No. 9,018,356), and anti-platelet-derived growth factor receptor antibody. (For example, anti-PDGFR antibodies as described in U.S. Patent No. 9,265,827), anti-Erb3 antibodies, anti-prolactin receptor antibodies (for example, anti-PRLR antibodies as described in U.S. Patent No. 9,302,015), anti-complement 5 antibodies (for example, anti-C5 antibodies as described in U.S. Patent No. 9,795,121), anti-TNF antibodies, anti-epidermal growth factor receptor antibodies (for example, anti-EGFR antibodies as described in U.S. Patent No. 9,132,192 or anti-EGFRvIII antibodies as described in U.S. Patent No. 9,475,875), anti-proprotein converters - Zezubutilisin kexin-9 antibody (e.g., anti-PCSK9 antibody as described in U.S. Patent No. 8,062,640 or U.S. Patent No. 9,540,449), anti-growth and differentiation factor-8 antibody (e.g., anti-GDF8 antibody, also known as anti-myostatin antibody as described in U.S. Patent No. 8,871,209 or No. 9,260,515), anti-glucagon receptor (e.g., anti-GCGR antibody as described in U.S. Patent No. 9,587,029 or No. 9,657,099), anti-VEGF antibody, anti-IL1R antibody, interleukin-4 receptor antibody Anti-IL4R antibodies (e.g., anti-IL4R antibodies as described in U.S. Patent Publication No. 2014 / 0271681A1, U.S. Patent No. 8,735,095 or No. 8,945,559), anti-interleukin-6 receptor antibodies (e.g., anti-IL6R antibodies as described in U.S. Patent No. 7,582,298, No. 8,043,617 or No. 9,173,880), IL1 antibodies, anti-IL2 antibodies, anti-IL3 antibodies, anti-IL4 antibodies, anti-IL5 antibodies, anti-IL6 antibodies, anti-IL7 antibodies, anti-interleukin-33 antibodies (e.g., U.S. Patent No. 9,453,072 or No. 9,637,Anti-IL33 antibodies (as described in Patent No. 535), anti-respiratory syncytial virus antibodies (e.g., anti-RSV antibodies as described in U.S. Patent Nos. 9,447,173 and 10,125,188 and U.S. Patent Publication No. 2019 / 0031741A1), anti-differentiation cluster 3 (e.g., anti-CD3 antibodies as described in U.S. Patent No. 9,657,102), anti-differentiation cluster 20 (e.g., anti-CD20 antibodies as described in U.S. Patent Nos. 9,657,102 and US20150266966A1 and U.S. Patent No. 7,879,984), anti-CD19 antibodies, anti-CD28 antibodies, anti-differentiation cluster 48 (e.g., as described in U.S. Patent No. 9,228,014) Antibodies are selected from the group consisting of anti-CD48 antibodies (such as those described in U.S. Patent No. 9,079,948), anti-Middle East Respiratory Syndrome virus (Middle East Respiratory Syndrome virus)The target protein is selected from the group consisting of anti-CD3 x anti-mucin 16 bispecific antibodies (as described in No. 102 and US20150266966A1), anti-CD3 x anti-Muc16 bispecific antibodies (e.g., anti-CD3 x anti-Muc16 bispecific antibodies), and anti-CD3 x anti-prostate-specific membrane antigen bispecific antibodies (e.g., anti-CD3 x anti-PSMA bispecific antibodies). In some embodiments, the target protein is absiximab, adalimumab, adalimumab-at, ad-trastuzumab, alemtuzumab, alirocumab, atezolizumab, avelumab, basiliximab, belimumab, benralizumab, bevacizumab, bezlotoximab, blinatumomab, brentuximab, vedotin, brodalumab, brolucizumab, canakinumab, capromab, pendetide, certolizumab Pegol, semiprimab, cetuximab, denosumab, dinutuximab, dupilumab, durvalumab, eculizumab, elotuzumab, emicizumab-kxwh, emtansinealirocumab, evinacumab, evolocumab, facinumab, golimumab, guselkumab, ibritumomab The following are selected from the group consisting of tiuxetan, idarucizumab, infliximab, infliximab-abda, infliximab-dyyb, ipilimumab, ixekizumab, mepolizumab, necitumumab, nesbakumab, nivolumab, obilutoxaximab, obinutuzumab, ocrelizumab, ofatumumab, oraratumab, omalizumab, panitumumab, pembrolizumab, pertuzumab, ramucirumab, ranibizumab, laxibakumab, reslizumab, linukumab, rituximab, sarilumab, secukinumab, silutuximab, tocilizumab, tocilizumab, trastuzumab, trevogrumab, ustekinumab, and vedolizumab.

[0070] In some embodiments, the protein in the complex is a recombinant protein containing an Fc moiety and another domain (e.g., an Fc fusion protein). In some embodiments, the Fc fusion protein is a receptor Fc fusion protein containing one or more extracellular domains of a receptor linked to the Fc moiety. In some embodiments, the Fc moiety includes a hinge region followed by the CH2 and CH3 domains of IgG. In some embodiments, the receptor Fc fusion protein contains two or more different receptor chains that bind to a single ligand or a plurality of ligands. For example, the Fc fusion protein is a trap protein such as an IL-1 trap (e.g., lilonacept containing an IL-1RAcP ligand-binding domain fused to an Il-1R1 extracellular domain fused to the Fc of hIgG1, U.S. Patent No. 6,927,044 (the whole of which is incorporated herein by reference)) or a VEGF trap (e.g., aflibercept or ziv-aflibercept containing an Ig domain 2 of VEGF receptor Flk1 fused to an Ig domain 3 of VEGF receptor Flt1 fused to the Fc of hIgG10). In other embodiments, the Fc fusion protein is an ScFv-Fc fusion protein containing one or more antigen-binding domains, such as variable heavy chain fragments and variable light chain fragments of an antibody linked to the Fc portion.

[0071] In some embodiments, proteins lacking an Fc moiety, such as recombinantly produced enzymes and minitraps, can also be prepared according to the present invention. Minitraps are trap proteins that use a polymerizing component (MC) instead of an Fc moiety, and are disclosed in U.S. Patents 7,279,159 and 7,087,411.

[0072] In some embodiments, the initial protein is in the form of a dry powder, e.g., a pulverized dry powder. In some embodiments, the protein is spray-dried powder (SDP). Using spray-dried protein instead of a protein solution has the advantages of higher protein packing in microparticles and better protein stability during the encapsulation process. In some embodiments, the dry protein molecules remain in a solid state throughout the encapsulation process and storage conditions, surrounded by a stabilizer. In some embodiments, the encapsulated spray-dried protein exhibits high recovery and low aggregates, as surface interactions may be minimized because only a small portion of the surface protein is exposed to the interface. In some embodiments, the protein is pulverized before encapsulation.

[0073] B. Particulates Several embodiments provide pharmaceutical compositions prepared using a disclosed non-aqueous membrane emulsion system. In some embodiments, the pharmaceutical composition contains microparticles having a polymer surface and a micronized protein core. In some embodiments, the microparticles are generally spherical. The microparticles and protein core may be nearly spherical or more irregular in shape. Therefore, as used herein, the term “diameter” means each and any of the following: (a) the diameter of the sphere circumscribing a microparticle or protein core; (b) the diameter of the largest sphere that fits within the boundary of the microparticle or protein core; (c) any measurement between the circumscribing sphere of (a) and the bounding sphere of (b) (including the average value between the two); (d) the length of the longest axis of the microparticle or protein core; (e) the length of the shortest axis of the microparticle or protein core; (f) any measurement between the length of the long axis (d) and the length of the short axis (e) (including the average value between the two); and / or (g) the equivalent diameter of a circle ("ECD") as volume or number-average diameter determined by microflow imaging (MFI), nanoparticle tracking analysis (NTA), or by light scattering methods such as static light scattering (SLS), dynamic light scattering (DLS), or laser diffraction analysis. Diameter is generally expressed in micrometers (μm or micron). Diameter can be determined by optical measurement or scanning electron microscopy measurement.

[0074] The microparticles produced by the non-aqueous emulsion method of this disclosure are multiple molecules of protein having low, very low, or near-zero amounts of water (e.g., 3% by weight or less of water). As used herein, the micronized protein particles have an ECD in the range of 2 microns to about 35 microns, or 2.0 to 50 μm, or 5.0 to 15.0 μm, 30 to 60 μm, or about 10 μm. The micronized protein particles are not limited to any specific protein entity and are suitable for the preparation and delivery of therapeutic proteins containing the above-mentioned proteins.

[0075] For example, protein particles may be pulverized by spray drying, freeze-drying and grinding, jet grinding, reversible precipitation in a non-solvent, granulation, gradual precipitation (US7,998,477 (2011)), supercritical fluid precipitation (US6,063,910 (2000)), or high-pressure carbon dioxide-induced particle formation (Bustami et al., Pharma. Res. 17:1360-66 (2000)). As used herein, the term “spray drying” means a method of producing a dry powder containing micron-sized particles from a slurry or suspension by using a spray dryer. A spray dryer uses a sprayer or spray nozzle to disperse the suspension or slurry into a spray of a controlled drop size. Spray drying can produce drop sizes of 10–500 μm. As the solvent (water or organic solvent) dries, the protein material dries into micron-sized particles, forming a powdery substance. Alternatively, in the case of a protein-polymer suspension, during drying, the polymer hardens a shell around the protein filling.

[0076] In some embodiments, the micronized protein is a VEGF trap protein. A pharmaceutical formulation for forming micronized VEGF trap protein particles may contain about 10 mg / mL to about 100 mg / mL of VEGF trap protein, about 1.0 to about 50 mg / mL of protein, about 10 mg / mL, about 15 mg / mL, about 20 mg / mL, about 25 mg / mL, about 30 mg / mL, about 35 mg / mL, about 40 mg / mL, about 45 mg / mL, about 50 mg / mL, about 55 mg / mL, about 60 mg / mL, about 65 mg / mL, about 70 mg / mL, about 75 mg / mL, about 80 mg / mL, about 85 mg / mL, about 90 mg / mL, about 95 mg / mL, or about 100 mg / mL of VEGF trap protein.

[0077] In some embodiments, the microparticles produced using the disclosed non-aqueous membrane emulsion system contain protein particle cores within the polymer surface and have diameters ranging from about 2 μm to about 70 μm, about 5 μm to about 65 μm, about 10 μm to about 60 μm, about 15 μm to about 55 μm, about 10 μm to about 50 μm, about 1.0 μm to 15 μm, about 20 μm, about 25 μm, or about 30 μm. The size variation largely reflects the thickness of the polymer surface, although the diameter of the protein core may contribute to the size variation to some extent.

[0078] In some embodiments, the microparticles formed by the disclosed non-aqueous emulsion method are fluid microparticle compositions. The disclosed fluid microparticle compositions can be suspended in a pharmaceutically acceptable excipient, such as pH-buffered saline. The fluid microparticle compositions can be administered parenterally, for example, using a syringe such as one having a 27G needle.

[0079] In some embodiments, microparticles are useful for the time-release or sustained release of protein therapeutics. In some embodiments, microsphere formulations are injected intravitreously, onto the choroid, or subcutaneously. For example, VEGF trapping microparticles are envisioned to be useful for the sustained release of VEGF trapping therapeutic proteins in the vitreous or suprachoroidal space for the treatment of vascular eye disorders, or for subcutaneous implantation for the sustained release of VEGF traps for the treatment of other disorders.

[0080] The microparticles of the present invention release proteins at a relatively constant rate over a long period of time, at least 60, 90, 120, or 150 days, in a physiological aqueous environment at approximately 37°C. In some embodiments, the microparticles have a burst of less than 15% after 24 hours, followed by a linear, sustained release of the drug.

[0081] Some embodiments provide compositions of microspheres produced using a non-aqueous membrane emulsion method disclosed herein, the compositions containing more than 100 mg of spray-dried protein. In some embodiments, the non-aqueous membrane emulsion method produces microparticles with a yield of more than 90%, a purity of more than 99%, and a w / w packing of more than 10% and a burst of less than 10%. [Examples]

[0082] Example 1: Synthesis of blank microspheres using H / F-based bulk emulsion Materials and methods Oil and aqueous-based emulsion systems are frequently used for the synthesis of polymer microparticles or nanoparticles, where hydrophobic polymer materials are dissolved in an organic phase and dispersed in an aqueous continuous phase. However, conventional aqueous-based emulsion systems are not ideal for water-soluble polymers, such as PEG, carboxymethylcellulose (CMC), and polymers that readily hydrolyze in the presence of water, including polyanhydrides, aliphatic polyesters with short intermediate blocks such as polylactic acid, and certain poly(amino acids) such as poly(glutamic acid). The following examples demonstrate the usefulness of the disclosed H / F emulsion system for producing the above-mentioned hydrolyzable or water-degradable polymer microparticles. In some embodiments, these polymers are first dissolved in a hydrocarbon solvent, including polar solvents (e.g., acetonitrile, tetrahydrofuran) and less polar solvents (e.g., DCM, chloroform). This polymer solution is then added to a continuous phase, a fluorocarbon liquid, such as FC-40 (e.g., Picosurf 1) containing FS. The emulsion is prepared by stirring, vortexing, or other compounding methods. The emulsion droplets are ultimately cured into polymer spheres by evaporation or extraction of the hydrocarbon solvent.

[0083] In a specific embodiment, as illustrated in Scheme 1 (Figure 1A), approximately 10%, 20%, 30%, and 40% w / v POE (200 μL) in DCM was added to FC-40 (2 mL) containing 0.5% w / w FS Pico-Surf® 1 (Sphere Fluidics) for the synthesis of blank POE microspheres via an H / F bulk emulsion. Emulsification was achieved by vortexing. The emulsion droplets were lighter than FC-40 and floated on top of the solution. Aliquots were taken and dropped onto glass slides for microscopic imaging. The microspheres were cured under vacuum with stirring for 3 hours. The cured polymer spheres in FC-40 were first vacuum filtered through a 0.22 micron PES membrane. The FC-40 passed through the filter, and the microspheres were retained. The microspheres were then washed with additional FC-40 and completely dried under vacuum. In another example using the same process, approximately 30% w / v of POE in DCM was used in the hydrocarbon phase, and approximately 0.01%, 0.1%, and 0.5% of FS in FC40 were used in the fluorocarbon phase to evaluate the effect of FS concentration.

[0084] result The presence of FS allowed the hydrocarbon-fluorocarbon mixture to form an H / F emulsion. In one example, DCM was dispersed in FC-40 (see structure of FC-40 in Figure 1B) as the H / F emulsion, and PFPE-PEG-PFPE was used as the FS (see structure of FS in Figure 1C). Increasing concentrations of FS were added to the FC-40 fluorocarbon phase. Tests showed that 0.1–5% w / w of FS was necessary to prevent coalescing of DCM droplets (Figure 2A). When less than 0.1% w / w of SF was added, a wider size distribution was observed. Without SF, the DCM droplets were unstable. The dispersed DCM droplets would fuse immediately, and the two phases would quickly separate. The results indicated that a sufficient amount of FS is needed to produce a stable H / F emulsion, and continuous stirring during the curing process is required to successfully produce polymer microspheres (Figure 2B).

[0085] When POE was added to DCM and vortexed in FC-40, droplets containing POE were formed. Evaporation of DCM under ambient conditions in an open container or under vacuum resulted in hardened droplets in POE microspheres (Figures 2A and 2B). Microsphere size was related to droplet size and POE content in the organic phase. Higher POE concentrations resulted in larger microsphere sizes (Table 1). [Table 2]

[0086] Example 2: Effect of homogenization rate Materials and methods 30% or 40% w / v POE (1 mL) in DCM was added to FC-40 (9 mL) containing 0.5% (w / w) FS FC-40, and emulsified using a VWR handheld homogenizer 200 with a VWR 7 mm × 95 mm sawtooth generator probe at one of three homogenization rates: low (approximately 50% of full power), medium (approximately 60% of full power), and high (approximately 70% of full power). The formed emulsion was stirred under vacuum. The formed microspheres were washed and dried under vacuum.

[0087] result As shown in Figures 3A-C, for 30% POE, a low homogenization rate resulted in larger microsphere sizes, while a high homogenization rate resulted in smaller sizes (Table 2). The same trend was observed for 40% POE. These results indicate that microsphere size can be controlled by adjusting the homogenization rate. [Table 3]

[0088] Example 3: General procedure for protein SDP encapsulation in POE microspheres using an S / H / F-based bulk emulsion method Materials and methods As shown in Figure 4, bulk emulsion synthesis can be divided into three steps: compounding, emulsification, and curing. The properties of the product will differ as different parameters are used in these three steps. The general procedure is described below.

[0089] For formulation, 10%–30% w / w total solid weight VEGF trap SDP (or fluorescently labeled SDP (F-SDP) for fluorescence imaging) was dispersed in 500 μL of ethyl acetate containing 10–35% w / w POE by vortexing and subsequent 5 minutes of sonication. These suspensions were then added to 9.5 mL of FC-40 containing 0.1–0.5% w / w FS. Emulsification could be achieved by stirring, vortexing, or homogenization using a benchtop homogenizer. The structure of the emulsion is shown in Figure 5. Immediately after emulsification, in-process aliquots were taken and dropped onto glass slides for microscopic imaging. The droplets were cured on the slides by evaporation under ambient conditions. To cure the microspheres, one of the following three methods was applied: (a) stirring the solution overnight in an open container under ambient conditions to allow evaporation of ethyl acetate; (b) stirring the solution under vacuum for at least 2 hours for faster solvent evaporation; and (c) adding NOVEC7500, or a mixture of FC-40 and NOVEC7500, to the emulsion while stirring. HFE acts as a co-solvent, assisting in the extraction of ethyl acetate from the hydrocarbon phase to the fluorocarbon phase and enabling a rapid curing process (usually within minutes).

[0090] Finally, the cured polymer spheres in FC-40 were first vacuum filtered through a 0.22 μm PES membrane. The FC-40 passed through the filter, and the microspheres were retained. The microspheres were then washed with additional FC-40 and completely dried under vacuum.

[0091] The microsphere size was measured by laser diffraction analysis using a Malvern Mastersizer 3000 with liquid sampling, after dispersing the product powder in a 0.01% w / v PVA solution. The morphology of the product was measured using a scanning electron microscope (SEM).

[0092] To measure the protein content of microspheres, a predetermined amount of microspheres was first dissolved in 200 μL of ethyl acetate, then extracted with a single stream of pure water, the aqueous phase was collected, and the turbid suspension was removed by centrifugation. The purity and concentration of the protein were measured by SEC-UPLC.

[0093] To measure burst release, a predetermined amount of microspheres was incubated in 1 mL of PBS at 37°C for 1 hour. The mixture was centrifuged, and the supernatant was subjected to SEC-UPLC for protein enrichment.

[0094] result The above results demonstrated formation when the H / F emulsion was stable due to the presence of sufficient SF. This aqueous emulsion can successfully generate blank POE spheres. This anhydrous method was again used to incorporate SDP into POE microspheres. In one example, 10% w / w total solid weight of VEGF-trapped F-SDP was introduced as a suspension in ethyl acetate (containing 20% ​​w / v POE), and this suspension in FC-40 (containing 0.5% w / w FS) was compounded by stirring and vortexing. Immediately after emulsification, aliquots were transferred to glass slides and microscopic imaging was performed. As shown in Figures 6A and 6B, the ethyl acetate dispersed into droplets in FC-40, and the SDP particles were clearly trapped within the ethyl acetate droplets. In contrast to the S / O / W system (data not shown), there was no indication of protein leakage into the fluorocarbon continuous phase. Importantly, in this H / F system, the SDP particles in the droplets retained their original concave shape from the powder state. Since the H / F system used to reconstitute the SDPs lacked water, the SDPs remained in their original solid particle form. After curing, POE microspheres containing single or multiple SDP particles could be clearly observed through brightly filed and fluorescence microscopy images (Figures 7A, 7B, and 7C). After evaporation of the hydrocarbon and fluorocarbon solvents on the glass slides, water was added to test burst release and encapsulation quality. As shown in Figures 8A-D, after placing the microsphere products in water, the SDP-encapsulated POE microspheres maintained their integrity. No immediate release of proteins was observed, and the shape of the SDP particles remained the same, indicating that the SDP particles were well protected by the polymer matrix and shielded from the aqueous environment. These results demonstrate that H / F emulsions are an effective solution for encapsulating proteins and other hydrophilic drugs within a polymer matrix, with the potential to achieve high encapsulation efficiency and high yield while minimizing burst release. These are all major challenges when using aqueous-based W / O / W or S / O / W methods.

[0095] The procedure disclosed herein is an example of using an S / H / F non-aqueous-based bulk emulsion method for protein SDP encapsulation in POE microspheres. This method is reproducible, scalable, and tunable. Product properties can be tuned and controlled by varying parameters in the formulation and process. The effects of some of these parameters are disclosed in Example 4.

[0096] Example 4: Effects of hydrocarbon solvents Materials and methods Fine particles were prepared as described in Example 2 using dichloromethane or ethyl acetate as the hydrocarbon. POE at 35% w / v in DCM and POE at 35% w / v in ethyl acetate were prepared. Protein powder with a total solid weight of 10% (10%) w / w was suspended in 0.5 mL of POE solution in DCM or ethyl acetate. These suspensions were transferred to 9.5 mL of FC-40 containing 0.5% w / w FS in a 20 mL scintillation vial. These mixtures were homogenized to produce an emulsion and stirred under house vacuum for 1.5 hours. The formed microspheres were isolated by filtration, washed with FC-40, and dried under vacuum.

[0097] result Figure 9 shows the size distribution of microparticles produced using the same formulation and process conditions, except for the type of hydrocarbon solvent (either dichloromethane or ethyl acetate). Microparticles produced using either hydrocarbon show encapsulation of spray-dried protein. Using dichloromethane results in larger microparticles. See Table 3 below. The results suggest that different sizes of microspheres can be obtained using different hydrocarbon solvents under the same formulation and process conditions. DCM produced larger microsphere sizes than ethyl acetate. Therefore, the hydrocarbon solvent can be intentionally selected to control microsphere size. [Table 4]

[0098] Example 5: Effect of protein filling amount Materials and methods Microparticles were prepared as described in Example 2 by varying only the protein filling amount. 35% POE in DCM was prepared. Protein powders with total solid weights of 5%, 10%, and 30% w / w were suspended in 0.5 mL of POE solution in DCM. These suspensions were transferred to 9.5 mL of FC-40 containing 0.5% w / w FS in a 20 mL scintillation vial. These mixtures were homogenized for approximately 1 minute to produce an emulsion, and then 6 mL of a 1:1 (v:v) mixture of Novec7500 and FC-40 was added to the emulsion within 1 minute. After stirring for a further 1 minute, the formed microspheres were isolated by filtration, washed with FC-40, and dried under vacuum.

[0099] result As shown in Table 4, increasing the amount of protein powder in the formulation resulted in larger POE microparticle sizes as measured by laser diffraction analysis, and also increased protein filling in the final POE microsphere product as observed by protein extraction experiments, bright-field, and confocal fluorescence microscopy. Bright-field images for 30% w / w protein powder filling showed darker, less transparent microspheres than those for 10% w / w protein powder, indicating that more drug was encapsulated within the microsphere product (Figures 10A and 10B). Representative confocal images confirmed that the SDPs were encapsulated in their original form within the POE matrix from cross-sectional views of the microspheres (Figures 11A and 11B). More SDP particles were observed in the 30% w / w filled microspheres. Again, the encapsulated SDPs retained their original concave shape, indicating that they remained intact throughout the manufacturing process. [Table 5]

[0100] Figures 12A and 12B are scanning electron microscope (SEM) images of microparticles filled with 5% w / w SDP and 10% w / w SDP, respectively.

[0101] Example 6: Design of Experiment (DOE) for encapsulation of SDP in POE microspheres using H / F bulk emulsification. Materials and methods DOE tests were performed to evaluate the influence of key synthesis factors in the designed space on the properties of the final product. Ten runs of the designed experiment were performed according to the general procedure described in Example 2. Protein powder filling, protein powder particle size (Dv(50) sizes were 2.2 μm and 5.6 μm, see SEM images in Figures 13A and 13B, respectively), polymer concentration, and HFE concentration were varied while keeping the following formulation and process conditions constant (e.g., volume of hydrocarbon and fluorocarbon phases, homogenization rate, FS concentration (Table 5)). Measured responses included microsphere size (Dv50, span by laser diffraction), encapsulation efficiency, burst emission at 37°C for 1 hour, and SEM images.

[0102] result The results of the DOE are summarized in Table 5. [Table 6]

[0103] Microsphere size (R 2 Custom-designed DOE fitting for (=0.76) revealed the main effects of protein powder filling and POE concentration (p-value < 0.05, see correlation results in Table 6). In addition, fitting for burst release (R 2The correlation coefficient (=0.92) indicates that only protein powder filling significantly affects burst release (p-value < 0.05, see correlation results in Table 7). The results suggest that increasing the amount of protein powder in the formulation leads to a higher payload in the final product, but also increases the burst release percentage. Burst release is likely caused by surface-adsorbed protein particles. The maximum amount of protein powder that can be internalized within polymer microspheres is determined by the physical space of a given microsphere size. Simply increasing the protein powder concentration in the formulation suspension does not increase drug encapsulation beyond a certain threshold, which was approximately 30% w / w in this example. [Table 7] [Table 8]

[0104] Example 7. Application of S / H / F emulsion-based encapsulation method to different proteins The disclosed H / F-based emulsion systems and processes may be platform technologies applicable to different polymers and therapeutic proteins. In specific examples of the present invention, recombinant IgG4 protein powder (MW: approximately 145 kDa), recombinant IgG1 protein powder (MW: approximately 146 kDa), or recombinant fusion protein protein powder (MW: approximately 64 kDa) were encapsulated in POE microspheres using a process similar to that of Example 2. The results are summarized in Table 8. The amount of encapsulated protein powder in the microsphere product was determined by extraction assays and matched to target values. The retention of protein purity for recombinant fusion protein and IgG1, or a slight decrease (less than 2%) for IgG4 after the encapsulation process, indicates good process suitability. [Table 9]

[0105] Other biodegradable polymers, such as PLGA and PLA, are also used in H / F-based emulsions. In a specific example of the present invention, fluorescently labeled VEGF trap F-SDP was encapsulated in PLGA (lactide:glycolide 50:50, Mw: 42-65 kDa, Sigma Aldrich) and PLA (alkyl ether-terminated, Mw: 18,000-28,000, Sigma Aldrich) microspheres by a similar method disclosed in Example 2. Other polymer ratios and molecular weights can also be used. Bright-field and fluorescence microscopy images showed that the protein powder was successfully encapsulated inside the polymer microspheres (Figures 14A-C for PLA and 15A-B for PLGA).

[0106] Example 8: Non-aqueous film emulsion Microparticles were manufactured using membrane emulsions with the materials listed in Table 9. [Table 10]

[0107] Membrane emulsification (ME) is a relatively new technique for the highly controlled production of particles, enabling good size control and a narrow size distribution. To date, many types of membranes have been developed for ME, including Shirasu Porous Glass (SPG), cellulose acetate, polymers, anodic porous alumina, and silicon microchannels. For the disclosed process, stainless steel membranes with laser-drilled pores were found to be optimal for the purpose, and commercially available equipment from Micropore Technologies (Redcar, UK) enables laboratory research processes and scale-up to GMP production. Some key characteristics of membrane technology include: 1. Strictly controlled membrane pore size allows all SDP particles below the limit to pass through the membrane. 2. Straight tubular channels without winding paths reduce the tendency for channel blockage by SDPs. 3. Fluorophilic membrane coatings provide good compatibility with the production of hydrocarbon (H / F) emulsions in fluorocarbons. Furthermore, the stainless steel membrane is robust, easy to clean, and sterilizable.

[0108] For each experiment, blank POE microspheres (RS001-Batch 1) or protein-encapsulated POE microspheres (RS001-Batch 2) were prepared by membrane emulsification using a conventional aqueous-based emulsion system. The preparation parameters are listed in Table 10. In Batch 1, blank POE microspheres were prepared using a 10% w / w POE solution in DCM as the dispersed phase and 1% polyvinyl alcohol (PVA) as the continuing phase. In Batch 2, microencapsulation was performed on VEGF-trap SDP (containing 1% Alex488-labeled VEGF traps) with a size D50=2.2 (D10=1.0, D90=3.8, span=1.24). The SDP was added to a 10 w / w% POE solution in DCM with an SDP:POE ratio of 9:1 (by weight). The mixture was vortexed and sonicated in an ultrasonic bath for 5 minutes to prepare a homogeneous suspension. The SDP suspension was immediately filled into a 10 mL BD syringe and supplied to an LDC-1 dispersion cell at a rate of 0.8 mL / min driven by a syringe pump. The emulsion was formed when the organic phase completely passed through a membrane with 30 μm pores while being stirred using 10 V DC power (approximately 1,015 rpm depending on viscosity). The formed emulsion was transferred to an uncapped beaker and allowed to harden into microspheres overnight under ambient conditions without stirring. The microsphere product was finally washed on a vacuum filter with MilliQ water and dried overnight under vacuum. [Table 11]

[0109] For another experiment, blank POE microspheres (batch 3) or protein-encapsulated POE microspheres (batch 4) were prepared by membrane emulsification using a novel non-aqueous fluorocarbon hydrocarbon emulsion system. The preparation parameters are listed in Table 11. In batch 4a, the above VEGF trap SDP (containing 1% Alexa488-labeled VEGF traps) was added to a hydrocarbon solvent DCM containing biodegradable or bio-erosive polymer POE. The mixture was vortexed and sonicated to form a homogeneous suspension. The SDP suspension was immediately filled into a syringe and supplied to an LDC-1 dispersion cell by syringe pump. The suspension was injected through a porous membrane with a pore size larger than that of protein powder particles into a continuous phase of fluorocarbon (e.g., FC-40) containing a fluorinated surfactant (e.g., Pico-Surf1) to form a fluorocarbon hydrocarbon emulsion (shown in Figure 16). Subsequent microsphere curing was achieved by removing the hydrocarbon solvent from the formed emulsion droplets by adding NOVEC7500, a hydrofluoroester, to the fluorocarbon as a cosolvent. The cured microspheres were collected, washed with FC-40 to remove excess fluorinated surfactants, and dried using vacuum filtration containing a PES filter. Finally, the product was dried under vacuum to remove residual solvent. A flowchart of the entire process is shown in Figure 17. [Table 12]

[0110] result As shown in Figure 18, SEM images of blank POE microspheres produced via a conventional aqueous-based emulsion system (Batch 1) and a non-aqueous-based emulsion system (Batch 3) demonstrate that while both methods yield spherical microparticles, they exhibit different surface morphologies. The aqueous-based method resulted in a highly porous surface due to the presence of water during the process, while the non-aqueous-based method, due to a completely anhydrous process, yielded a smooth microsphere surface without clearly defined pores.

[0111] Figure 19 shows a comparison of the results obtained from both methods for microencapsulation of VEGF-trapped SDPs into POE microspheres. Aqueous membrane emulsification (batch 3) yielded good monodisperse microspheres, but the surface was highly porous and contained water channels. The monodispersity of microspheres obtained from non-aqueous membrane emulsification was worse than that of the aqueous version, but this could be further improved by adjusting process parameters. Furthermore, many SDPs were observed to be embedded on the surface of the POE microspheres. These surface-located SDPs may contribute to the burst release of proteins after the microspheres were incubated in buffer (Tables 11 and 12).

[0112] Fluorescence microscopy images revealed the morphology and distribution of the protein SDP inside the POE microspheres (Figure 20). In batch 3, the SDP was reconstituted by water during the encapsulation process and fused into larger droplets inside the microspheres. Conversely, in batch 4, the SDP encapsulated inside the microspheres retained its original raisin-shaped structure, indicating that the SDP maintained its integrity after the process, as there was no protein reconstitution by water.

[0113] The encapsulation efficiencies (measured protein filling / theoretical protein filling in the product) for batches 3 and 4 were determined to be 35.0% and 80.7%, respectively (Table 12). The more than twofold increase in encapsulation efficiency for the non-aqueous system suggests that SDPs are better retained in hydrocarbon droplets and less diffused into the continuous phase compared to the aqueous system. The purity of the proteins encapsulated in the POE microspheres (percentage of monomers) was measured by size exclusion chromatography (SEC). Batch 4 showed good retention of protein purity after the entire encapsulation process. [Table 13]

[0114] In the above specification, the present invention is described in relation to its particular embodiments, and many details are presented for illustrative purposes. However, it will be apparent to those skilled in the art that the present invention is susceptible to additional embodiments, and that some of the details described herein may vary considerably without departing from the fundamental principles of the invention.

[0115] The present invention may be embodied in other specific forms without departing from its spirit or essential attributes, and therefore, it is necessary to refer to the appended claims that define the scope of the invention rather than the foregoing specification.

Claims

1. 1. A method for producing a polymer-coated microparticle, comprising the steps of: combining a finely divided protein powder and a polymer in a hydrocarbon solvent to form a first non-aqueous solution; agitating the first non-aqueous solution to form a suspension; feeding the suspension into a dispersion cell, where the suspension is injected through a porous membrane into a continuous phase comprising a fluorocarbon liquid and a fluorosurfactant under cocurrent flow of the continuous phase to form a hydrocarbon-in-fluorocarbon emulsion; adding a hydrofluoroether to said hydrocarbon-in-fluorocarbon emulsion; removing the hydrocarbon solvent to provide a hardened microparticle; and removing the fluorocarbon liquid to isolate the microparticles, the microparticles comprising a protein encapsulated within a polymer matrix.

2. 10. The method of claim 1, further comprising removing residual fluorosurfactant from the particulates by washing the particulates in the fluorocarbon liquid, removing the fluorocarbon by vacuum, and collecting the particulates using a polyethersulfone membrane filter.

3. The method of claim 1 or 2, wherein the fluorocarbon liquid comprises perfluorinated C5-C18 compounds.

4. The method of any one of claims 1 to 3, wherein the hydrocarbon solvent is selected from the group consisting of dichloromethane, chloroform, toluene, ethyl acetate, tetrahydrofuran, or combinations thereof.

5. The method of any one of claims 1 to 4, wherein the fluorocarbon solution comprises 1,1,2,2,3,3,4,4,4-nonafluoro-N,N-bis(1,1,2,2,3,3,4,4,4-nonafluorobutyl)butan-1-amine.

6. The method of any one of claims 1 to 5, wherein the fluorosurfactant comprises perfluoropolyether-b-polyethylene glycol-b-perfluoropolyether.

7. The method of any one of claims 1 to 6, wherein the polymer comprises a polyorthoester (POE).

8. The method of any one of claims 1 to 6, wherein the polymer is selected from the group consisting of polylactic acid and poly(lactic-co-glycolic acid).

9. The method of any one of claims 1 to 8, wherein the hydrofluoroether is 2-(trifluoromethyl)-3-ethoxydodecafluorohexane.

10. The method according to any one of claims 1 to 9, wherein the membrane is a fluorophilically coated stainless steel membrane.

11. The method of claim 10, wherein the pores of the membrane are between 3 μm and 300 μm in diameter.

12. 12. The method of any one of claims 1 to 11, wherein the fluorosurfactant is present in the fluorocarbon liquid at about 0.1% to 5% w / v.

13. The method according to any one of claims 1 to 12, wherein the protein powder to polymer ratio is between 0.1% and 30%.

14. The method of any one of claims 1 to 12, wherein the finely divided powder is produced from an antibody or antigen-binding fragment thereof, a fusion protein, or a recombinant protein.

15. 15. The method of claim 14, wherein the fusion protein is a vascular endothelial growth factor (VEGF) trap fusion protein or a truncated version thereof.

16. 16. The method of claim 14 or 15, wherein the VEGF trap fusion protein is aflibercept.

17. 17. The method of any one of claims 1 to 16, wherein the supply of the suspension is at a rate of from 0.1 ml / min to 1.0 ml / min.

18. The method according to any one of claims 1 to 17, wherein the suspension is a homogenous suspension.

19. The method of any one of claims 1 to 18, wherein the microparticle comprises a single core-shell structure.

20. The method of any one of claims 1 to 19, wherein at least one microparticle comprises a plurality of cores dispersed within the polymer.

21. 21. The method of any one of claims 1 to 20, wherein the microparticles include microparticles comprising a combination of single core structures encapsulated by a polymer and microparticles comprising multi-core structures encapsulated by a polymer.

22. The method of any one of claims 1 to 21, wherein the microparticles have a diameter of from 1 μm to 200 μm.

23. The method of any one of claims 1 to 22, wherein the microparticles have a median diameter of between 30 μm and 60 μm.

24. The method of any one of claims 1 to 23, wherein the protein powder is micronized by spray drying, electrospray drying, reversible precipitation, spray freezing, microtemplating, or a combination thereof.

25. 25. The method of any one of claims 1 to 24, wherein the suspension is formed using homogenization, vortexing, sonication, cavitation, stirring, agitation, churning, whisking, shaking, emulsification, or a combination thereof.

26. A method according to any one of the preceding claims, wherein the hydrocarbon solvent is removed by evaporation.

27. The method of any one of claims 1 to 25, wherein the fluorocarbon liquid is removed by vacuum filtration.

28. A microparticle produced by the method of any one of claims 1 to 27, which is a sustained release microparticle.

29. 30. A sustained release composition comprising the microparticle of claim 28.

30. 30. The microparticle of any one of claims 1 to 29, wherein the microparticle has few or no pores or channels in the polymer cortex.

31. A method for producing a polymer-coated microparticle, comprising the steps of: combining a polymer and 1%-30% w / w all solids spray dried protein suspended in a hydrocarbon solution to form a first non-aqueous solution; agitating the first non-aqueous solution to form a suspension; feeding the suspension to a dispersion pump where the suspension is injected through a porous membrane into a continuous phase comprising a fluorocarbon liquid and 0.1% to 5.0% w / v fluorosurfactant under cocurrent flow of the continuous phase to form a hydrocarbon-in-fluorocarbon emulsion; removing the hydrocarbon solvent to provide a hardened polymer-coated microparticle; and removing the fluorocarbon liquid to isolate the microparticles, wherein the polymer-coated microparticles comprise a protein encapsulated within a polymer matrix.

32. 32. The method of claim 31 further comprising the step of adding a hydrofluoroether to the fluorocarbon liquid of the hydrocarbon-in-fluorocarbon emulsion prior to removing the hydrocarbon solvent.

33. 33. The method of claim 32, wherein the hydrocarbon solution is removed by evaporation at ambient atmospheric pressure or under vacuum.

34. 34. The method of claim 33, wherein the polymer-coated microparticles are harvested by vacuum filtration.

35. 33. The method of claim 31 or 32, wherein the spray-dried protein is an antibody, a recombinant protein, a fusion protein, or a fragment thereof.

36. 36. The method of claim 35, wherein the protein is a VEGF trap protein or a truncated VEGF trap protein.

37. 32. The method of claim 31 , wherein the hydrocarbon solution is selected from the group consisting of dichloromethane, chloroform, toluene, ethyl acetate, tetrahydrofuran, or combinations thereof.

38. 38. The method of any one of claims 31 to 37, wherein the fluorocarbon liquid comprises trifluoromethyl)bis(1,1,2,2,3,3,4,4,4-nonafluorobutyl)amine.

39. 40. The method of claim 38, further comprising harvesting the polymer-coated microparticles.

40. 40. A microparticle produced by any one of the methods according to claims 31 to 39.

41. 41. A pharmaceutical composition comprising the microparticle of claim 40.

42. 42. The pharmaceutical composition of claim 41, further comprising one or more excipients.

43. 42. The pharmaceutical composition of claim 41, wherein the pharmaceutical composition is a sustained release composition.

44. The pharmaceutical composition of any one of claims 41 to 43, wherein the pharmaceutical composition is formulated for parenteral administration.

45. The method of claim 3, wherein the hydrofluoroether comprises 4-ethoxy-1,1,1,2,2,3,3,4,5,6,6,6-didecafluoro-5-(trifluoromethyl)hexane.